A newly developed lab-designed molecule, JM2, may offer a promising therapy to combat glioblastoma recurrence by targeting the tumor’s most resilient cells. Researchers discovered that glioblastoma stem cells rely on the protein connexin 43’s interaction with microtubules—an interaction disrupted by JM2.
